Medical Device Complaint Management Market: as the FDA's Quality Management System Regulation enforcement date arrives and Veeva begins rolling AI agents across its quality applications, two forces that have moved independently for two years are converging on the same calendar, so device manufacturers that have not yet modernised their complaint management infrastructure now face both a hard regulatory deadline and a genuinely more capable software generation at the same time, and the platforms that can demonstrate QMSR-ready compliance architecture combined with working AI-assisted triage are positioned to win the resulting wave of replacement decisions.

The global medical device complaint management market size was USD 6.24 Billion in 2025 and is expected to register a revenue CAGR of 8.6% during the forecast period. Market revenue growth is driven by factors such as the FDA's Quality Management System Regulation enforcement converting harmonised complaint documentation standards into a mandatory compliance requirement, AI-powered complaint analysis reducing investigation time and improving root cause accuracy, and cloud-based platform adoption displacing legacy on-premises complaint management infrastructure. The first driving factor is FDA Quality Management System Regulation enforcement, which harmonises 21 CFR Part 820 with ISO 13485:2016 and directly shapes complaint handling and documentation requirements for every US medical device manufacturer. Product surveillance and regulatory compliance services account for more than 56% of total 2025 market revenue, reflecting the centrality of ongoing compliance monitoring to overall complaint management spend. The second driving factor is AI-powered complaint analysis, which reduces investigation time and improves root cause identification accuracy relative to manual complaint review processes. The third driving factor is cloud-based platform adoption, as device manufacturers migrate from legacy on-premises complaint management systems to scalable, continuously updated cloud infrastructure. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single regulatory enforcement deadline converts an optional software modernisation decision into a mandatory compliance investment for every affected manufacturer simultaneously, which lets complaint management platform vendors capture a concentrated wave of replacement and upgrade decisions within a defined window rather than the more gradual, dispersed adoption pattern that voluntary technology upgrades typically follow. Because the FDA's Quality Management System Regulation enforcement date applies uniformly to every US medical device manufacturer regardless of company size or current system maturity, manufacturers still operating legacy or manual complaint processes face a hard compliance deadline that a purely competitive or efficiency-driven software upgrade decision would not create, so platform vendors see demand concentrate into the specific window immediately surrounding the enforcement date rather than spreading evenly across years. As a result, demand and revenue share are concentrating around platforms that can demonstrate QMSR-ready compliance architecture ahead of the enforcement deadline, and the forecast reflects this regulatory-deadline-driven adoption wave as a distinct, time-bound driver rather than a steady-state demand pattern. For instance, in February 2026, FDA enforcement of the Quality Management System Regulation began, requiring all US medical device manufacturers to comply with the harmonised 21 CFR Part 820 and ISO 13485:2016 framework, directly converting complaint management software modernisation from a discretionary investment into a compliance necessity for the industry's full manufacturer base. These are some of the key factors driving revenue growth of the market.

Because any software used to manage regulated complaint records must undergo formal validation demonstrating electronic record and signature integrity under 21 CFR Part 11, even a cloud-based platform requires a genuine validation project before a manufacturer can rely on it for regulated complaint handling, which adds implementation time and cost beyond the software subscription itself.

Integration complexity with existing enterprise resource planning and quality systems is a second constraint, because a complaint management platform rarely operates in isolation and must exchange data reliably with a manufacturer's broader quality management, manufacturing, and customer service systems, and integration projects between disparate systems frequently exceed initial timeline and budget estimates.

Smaller manufacturer cost sensitivity is a third constraint, since enterprise-grade complaint management platforms carry subscription costs that can represent a meaningful expense for smaller device manufacturers and startups, which creates a bifurcated market between well-resourced enterprise adopters and cost-constrained smaller companies still relying on manual or basic spreadsheet-based processes.

These factors substantially limit medical device complaint management market growth over the forecast period.

The clearest driver of demand is FDA Quality Management System Regulation enforcement, which harmonises 21 CFR Part 820 with ISO 13485:2016 and directly shapes complaint handling and documentation requirements for the entire US medical device manufacturer base. A regulation that changes the specific documentation and process standards a complaint management system must support creates an immediate compliance gap for any manufacturer whose existing system was built around the prior standard, so the enforcement date functions as a hard deadline that concentrates software modernisation decisions into a defined window rather than allowing gradual, voluntary adoption. Product surveillance and regulatory compliance services account for more than 56% of total 2025 market revenue, and FDA enforcement of the QMSR began in February 2026, following the Final Rule's original publication on January 31, 2024, requiring all US medical device manufacturers to comply with the harmonised framework. The effect on the market is that complaint management platform demand is concentrated into the specific window surrounding the enforcement deadline, with vendors who can demonstrate QMSR-ready architecture positioned to capture this compressed decision cycle. These are some of the key factors driving revenue growth of the market.

The second driver is AI-powered complaint analysis, which reduces investigation time and improves root cause identification accuracy relative to manual complaint review processes that have historically dominated this function. Manual complaint investigation requires a quality engineer to read through unstructured complaint text and manually classify root cause, a time-consuming process prone to inconsistency across different reviewers, so an AI system trained to triage and classify complaint patterns can materially compress investigation time while improving consistency, directly addressing a documented operational bottleneck. Veeva Systems announced its major Veeva AI initiative in April 2025, adding AI agents across its Vault Platform applications including quality management, with agents specifically targeting clinical, regulatory, safety, and quality functions planned for rollout throughout 2026. The effect on the market is that AI-enabled complaint triage and root cause classification capability is becoming a standard procurement expectation for enterprise-grade complaint management platforms rather than an experimental feature. These are some of the key factors driving revenue growth of the market.

FDA QMSR enforcement began in February 2026, two years after the January 2024 Final Rule publication. Every US medical device manufacturer now faces a hard compliance deadline that has concentrated complaint management platform modernisation decisions into a single defined window.

The third driver is cloud-based platform adoption, as device manufacturers migrate from legacy on-premises complaint management systems to scalable, continuously updated cloud infrastructure. An on-premises complaint management system requires the manufacturer's own IT team to manage upgrades, security patching, and regulatory feature updates, while a cloud-based platform shifts that ongoing maintenance burden to the vendor, which is particularly valuable during a period of active regulatory change like the QMSR transition when platform capability needs to evolve quickly. The effect on the market is that cloud-based deployment is becoming the default architecture choice for new complaint management platform purchases, with on-premises systems increasingly limited to large enterprises with existing validated infrastructure they are not yet ready to replace. These are some of the key factors driving revenue growth of the market.

However, the medical device complaint management market faces severe adoption constraints from lengthy software validation requirements under 21 CFR Part 11 and integration complexity with existing enterprise resource planning and quality systems.

Because any software used to manage regulated complaint records must undergo formal validation demonstrating electronic record and signature integrity under 21 CFR Part 11, even a cloud-based platform with AI capability like Veeva's expanding Vault Platform requires a genuine validation project before a manufacturer can rely on it for regulated complaint handling, which adds implementation time and cost beyond the software subscription itself.

Integration complexity with existing enterprise resource planning and quality systems compounds this, because a complaint management platform rarely operates in isolation and must exchange data reliably with a manufacturer's broader quality management, manufacturing, and customer service systems, and integration projects between disparate systems frequently exceed initial timeline and budget estimates.

Smaller manufacturer cost sensitivity is the third constraint, since enterprise-grade complaint management platforms carry subscription costs that can represent a meaningful expense for smaller device manufacturers and startups, which creates a bifurcated market between well-resourced enterprise adopters and cost-constrained smaller companies still relying on manual or basic spreadsheet-based processes.

These factors substantially limit medical device complaint management market growth over the forecast period.

Based on service, the global medical device complaint management market is segmented into product surveillance and regulatory compliance, complaint log and intake management, investigation and root cause analysis, and CAPA management. Product surveillance and regulatory compliance holds the largest revenue share, accounting for more than 56% of total market revenue, because ongoing compliance monitoring spans the full breadth of a manufacturer's regulatory obligations beyond individual complaint handling, which suits a market where continuous compliance activity commands the largest revenue category. Complaint log and intake management is expected to register the fastest revenue growth rate in the global medical device complaint management market over the forecast period, driven by AI-powered intake classification tools that are transforming what was historically the most manual, labour-intensive stage of the complaint process.

Based on deployment, the global medical device complaint management market is segmented into cloud-based and on-premises deployment models. Cloud-based deployment holds a significant revenue share and is expected to register the fastest revenue growth rate in the global medical device complaint management market over the forecast period, driven by manufacturers seeking scalable infrastructure that shifts ongoing maintenance burden to the vendor during a period of active regulatory change. On-premises deployment remains established among large enterprises with existing validated infrastructure, particularly those with legacy TrackWise Digital or comparable enterprise ERP-linked systems not yet ready for full cloud migration.

Enterprise QMS software type is expected to account for the largest revenue share in the global medical device complaint management market during the forecast period

Based on software type, the global medical device complaint management market is segmented into enterprise QMS and purpose-built medtech QMS platforms. Enterprise QMS platforms, including MasterControl, TrackWise Digital, and Veeva, hold the largest revenue share, because their broader life sciences customer base and integration breadth suit large, multi-product manufacturers with complex compliance needs spanning quality, regulatory, and safety functions simultaneously. Purpose-built medtech QMS platforms, exemplified by Greenlight Guru's more than 1,100 medical device clients, are expected to register the fastest revenue growth rate in the global medical device complaint management market over the forecast period, driven by smaller and growth-stage device manufacturers seeking QMSR-ready workflows without the implementation complexity of a broader enterprise platform.

Based on regional analysis, the medical device complaint management market in North America accounted for largest revenue share in 2025. The United States leads because the FDA's QMSR enforcement deadline creates the most immediate and quantifiable compliance driver of any national market globally, and because MasterControl, Greenlight Guru, and Veeva Systems all maintain their primary commercial and development presence in the US market. The concentration of FDA-registered device establishments in the country also means new complaint management platform capability is typically adopted in the United States first, driven directly by the domestic regulatory enforcement timeline.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Freyr's RegOps complaint management module, launched for EU MDR compliance and Eudamed automated submissions, reflects the region's parallel but distinct regulatory compliance driver. The result is steady rather than rapid growth, shaped more by EU MDR and Eudamed submission requirements than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent two of the largest national markets within the region, driven by expanding domestic device manufacturing and increasing export-market regulatory compliance requirements. The region's rapidly scaling device manufacturing base leaves considerably more room for growth than in the already QMSR-compliance-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding device manufacturing driving early complaint management platform adoption. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the data centre and networking hardware that Latin American cloud infrastructure providers depend on, an effect expected to run through 2026 and slow medical device complaint management platform adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding medical device manufacturing investment and the UAE's regional distribution hubs represent the primary investment centres for complaint management platform adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the regulatory compliance infrastructure needed to support advanced complaint management systems at scale.